Search results for "cholangiocarcinoma"

showing 10 items of 69 documents

Assessing the impact of COVID-19 on liver cancer management (CERO-19)

2021

[Background & Aims] The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic.

Hepatocellular carcinomaLCmedicine.medical_treatment:diagnóstico::toma de decisiones clínicas [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]NursesRC799-869Liver transplantationCholangiocarcinomaClinical trialsENS-CCAInterquartile rangeDecisió Presa dePandemic:Other subheadings::/diagnosis [Other subheadings]:virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES]CERO-19Pandèmia de COVID-19 2020-Immunology and AllergyiCCA intrahepatic cholangiocarcinomaCOVID-19 coronavirus disease 2019Liver Cancer Outcome in the COVID-19-pandemic ProjectSettore MED/12 - Gastroenterologiaddc:617IQRGastroenterologyBCLC Barcelona Clinic Liver Cancer:Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES]:neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias hepáticas [ENFERMEDADES]Diseases of the digestive system. GastroenterologyManagementClinical PracticeClinical trialEuropean Network for the Study of Cholangiocarcinoma:Diagnosis::Clinical Decision-Making [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Fetge - Malalties - DiagnòsticInterquartile rangeLiver cancerLiver cancerPROGRESSION-FREE SURVIVALLiver Cancermedicine.medical_specialtyCoronavirus disease 2019 (COVID-19):Otros calificadores::/diagnóstico [Otros calificadores]610 Medicine & health:Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms [DISEASES]LT liver transplantationArticleBarcelona Clinic Liver CancerInternal MedicinemedicineENS-CCA European Network for the Study of CholangiocarcinomaHepatologybusiness.industryCERO-19 Liver Cancer Outcome in the COVID-19-pandemic ProjectCOVID-19IQR Interquartile rangemedicine.diseaseBCLCClinical trialEmergency medicineObservational study610 Medizin und GesundheitbusinessHCC hepatocellular carcinomaLC liver cancerSARS-CoV-2 severe acute respiratory syndrome coronavirus-2
researchProduct

Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules

2018

Background & Aims The use of contrast enhanced ultrasound (CEUS) for the diagnosis of hepatocellular carcinoma (HCC) in cirrhosis was questioned because of the risk of a false positive diagnosis in cases of cholangiocarcinoma. The American College of Radiology has recently released a scheme (CEUS Liver Imaging Reporting and Data System [LI-RADS®]) to classify lesions at risk of HCC investigated by CEUS. The aim of the present study was to validate this LI-RADS scheme for the diagnosis of HCC. Methods A total of 1,006 nodules from 848 patients with chronic liver disease at risk of HCC were collected in five Italian centers and retrospectively analyzed. Nodules were classified as LR-5, (HCC) …

Liver CirrhosisMaleCirrhosisContrast enhanced ultrasoundContrast MediaChronic liver diseaseGastroenterology030218 nuclear medicine & medical imagingCholangiocarcinoma0302 clinical medicineDiagnosisMedicineTomographyWashoutUltrasonographyUltrasoundLiver NeoplasmsMiddle AgedMagnetic Resonance ImagingX-Ray ComputedLiverHepatocellular carcinoma030211 gastroenterology & hepatologyFemaleRadiologymedicine.symptomAlgorithmsContrast-enhanced ultrasoundAdultmedicine.medical_specialtyCarcinoma HepatocellularDiagnosis Differential03 medical and health sciencesInternal medicineHumansDiagnostic ErrorsneoplasmsAgedLiver Imaging Reporting And Data System (LI-RADS)Hepatologybusiness.industryCarcinomaSettore MED/09 - MEDICINA INTERNAReproducibility of ResultsHepatocellularRetrospective cohort studyHistologyNodule (medicine)medicine.diseaseImage Enhancementdigestive system diseasesArterial hyperenhancementDifferentialbusinessTomography X-Ray Computed
researchProduct

Sicily Network for Liver Cancer: A Multidisciplinary Network Model for the Management of Primary Liver Tumors

2020

Background: The management of primary liver tumors requires the involvement of multiple specialist skills and the best possible treatment in terms of cost, risk, and benefit that could be provided by hepatobiliary or transplant surgeon, interventional radiologist, hepatologist, radiotherapist, or oncologist is needed to be chosen for each patient. This is particularly relevant for hepatocellular carcinoma (HCC), that is the most common primary liver tumor, and it occurs in more than 90% of cases in the setting of cirrhosis. Methods: To address the increasing complexity of cancer care, multidisciplinary tumor boards (MDTBs) have evolved to offer patients appropriate and tailored cancer treat…

Liver Cirrhosismedicine.medical_specialtyCirrhosisLiver tumorCarcinoma HepatocellularLiver Cirrhosicancer treatmentliver cancerMultidisciplinary approachHealth caremedicineHumansIntensive care medicineSicilyPatient Care Teambusiness.industryLiver Neoplasmshealth care modelCancerhepatocellular carcinomamedicine.diseaseSurgeryhealth care modelsLiver NeoplasmSicily.Hepatocellular carcinomanetworkSurgeryTransplant surgeonLiver cancerbusinesscholangiocarcinomaDelivery of Health CaremultidisciplinaryHuman
researchProduct

Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract can…

2019

Background To date, the cornerstone of treatment in patients with advanced or metastatic cholangiocarcinoma (CCA) is systemic chemotherapy based on a combination of gemcitabine and a platinum derivative. Other therapeutic approaches including targeted agents and tyrosine kinase inhibitors (TKI) have demonstrated disappointing results, highlighting the complexity of CCA. Recently, drugs aiming at the inhibition of HER-receptors have shown first therapeutic benefit in patients with late stage disease. The aim of this phase I study was to test the dose level toxicities (DLTs), safety and efficacy of afatinib, a highly specific panErbB family receptor TKI, in chemotherapy naive patients with ad…

Male0301 basic medicineOncologyCancer ResearchAfatinibDeoxycytidineTranslational Research BiomedicalCholangiocarcinoma0302 clinical medicineSurgical oncologyAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Metastasismedia_commonAged 80 and overpanHER inhibitionMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensImmunohistochemistryErbB ReceptorsBiliary Tract NeoplasmsTreatment OutcomeOncology030220 oncology & carcinogenesisBiomarker (medicine)FemaleTyrosine kinaseSignal TransductionResearch Articlemedicine.drugAdultDrugmedicine.medical_specialtyBIBW 2992media_common.quotation_subjectEGFRAfatiniblcsh:RC254-28203 medical and health sciencesInternal medicineGeneticsmedicineHumansProgression-free survivalAgedNeoplasm StagingCisplatinbusiness.industryGemcitabineGemcitabine030104 developmental biologyCisplatinbusinessBiomarkersBMC Cancer
researchProduct

Endoscopic cytology in biliary strictures. Personal experience

2008

The differential diagnosis between malignant and benign biliary strictures is the cornerstone of the management of jaundiced patients. The aim of our study is to define the role of cytology of the bile withdrawn during endoscopic retrograde cholangiopancreatography (ERCP), to reach a diagnosis of the nature of biliary stricture.This retrospective study was conducted on 67 consecutive patients affected of ingravescent obstructive jaundice who underwent ERCP+/-PTE (percutaneous transhepatic endoscopic)+bile withdrawn+stenting. We founded hilar stricture in 21 patients (31.3%), middle third the common duct stricture in 17 (25.3%), and lower third stricture in 28 patients (41.4%). In one patien…

MaleBile Duct DiseasesConstriction PathologicSensitivity and SpecificityCholangiocarcinomaDiagnosis DifferentialPredictive Value of TestsBileHumansAgedRetrospective StudiesAged 80 and overCholangiopancreatography Endoscopic RetrogradeCitology biliary cancerChi-Square DistributionBiopsy NeedleMiddle AgedPancreatic NeoplasmsJaundice ObstructiveSettore MED/18 - Chirurgia GeneraleTreatment OutcomeBile Duct NeoplasmsDrainageFemaleStentsFollow-Up Studies
researchProduct

The expression of HSP27 is associated with poor clinical outcome in intrahepatic cholangiocarcinoma.

2007

Abstract Background The heat shock proteins (HSPs) 27-kDa (HSP27) and 72-kDa (HSP72), are ubiquitous chaperone molecules inducible in cells exposed to different stress conditions. Increased level of HSPs are reported in several human cancers, and found to be associated with the resistance to some anticancer treatments and poor prognosis. However, there is no study of the relationship between HSPs expression and patient's prognosis in intrahepatic cholangiocarcinoma (IHCCA). In this exploratory retrospective study, we investigated the expressions of HSP27 and HSP72 as potential prognostic factors in IHCCA. Methods Thirty-one paraffin-embedded samples were analyzed by immunohistochemical meth…

MaleCancer ResearchHSP27 Heat-Shock ProteinsMitosisHSP72 Heat-Shock ProteinsBile Duct Neoplasmlcsh:RC254-282CholangiocarcinomaImmunoenzyme TechniquesNecrosisLymphocytes Tumor-InfiltratingHsp27Surgical oncologyHeat shock proteinGeneticsBiomarkers TumorMedicineHumansNeoplasm InvasivenessSurvival rateIntrahepatic CholangiocarcinomaHeat-Shock ProteinsAgedCell ProliferationRetrospective Studiesbiologybusiness.industryRetrospective cohort studyMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisNeoplasm ProteinsSurvival RateBile Ducts IntrahepaticOncologyBile Duct NeoplasmsImmunologybiology.proteinCancer researchFemaleStem cellbusinessMolecular ChaperonesResearch ArticleBMC cancer
researchProduct

The associated expression of Maspin and Bax proteins as a potential prognostic factor in intrahepatic cholangiocarcinoma

2006

Abstract Background Maspin, a member of the serpin family, is a suppressor of tumor growth, an inhibitor of angiogenesis and an inducer of apoptosis. Maspin induces apoptosis by increasing Bax, a member of the Bcl-2 family of apoptosis-regulating proteins. In this exploratory study, we investigated the associated expression of Maspin and Bax proteins as a potential prognostic factor in intrahepatic cholangiocarcinoma (IHCCA). Methods Twenty-two paraffin-embedded samples were analyzed by immunohistochemical methods using Maspin, Bax and CD34 antibodies. Maspin was scored semiquantitatively (HSCORE). Apoptosis was assessed using an antibody against cleaved caspase-3. Results The strong relati…

MaleCancer ResearchPathologymedicine.medical_specialtyAngiogenesisApoptosisCaspase 3Kaplan-Meier EstimateSerpinlcsh:RC254-282law.inventionCholangiocarcinomaBcl-2-associated X proteinlawBiomarkers TumorGeneticsmedicineHumansGenes Tumor SuppressorSerpinsIntrahepatic CholangiocarcinomaAgedbcl-2-Associated X ProteinbiologyCaspase 3business.industryMicrocirculationLiver NeoplasmsMaspinMiddle AgedPrognosislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensNeoplasm ProteinsEnzyme ActivationOncologyApoptosisCancer researchbiology.proteinSuppressorFemalebusinessResearch ArticleBMC Cancer
researchProduct

Expression of L- and M2-pyruvate kinases in proliferating oval cells and cholangiocellular lesions developing in the livers of rats fed a methyl-defi…

1994

Male outbred Sprague-Dawley rats were fed a choline-deficient diet containing 0.1% w/w DL-ethionine (CDE) for up to 22 weeks. The expression of the pyruvate kinase isoenzymes L (L-PK) and M2 (M2-PK) was immunohistochemically analyzed in liver slices from rats killed 4, 10, 14 and 22 weeks after starting the treatment. M2-PK was detected in bile duct epithelial cells of untreated rats and in proliferating oval cells, cholangiofibroses and cholangiofibromas of CDE-fed animals. Thus, M2-PK can be viewed as a positive marker of the bile duct epithelial/oval cell compartment. L-PK, a parenchymal cell-specific protein in untreated rat liver, was not present in proliferating oval cells, but was co…

MaleCancer ResearchPathologymedicine.medical_specialtyNecrosisLiver cytologyPyruvate KinaseCellBiologyCholangiocarcinomaRats Sprague-DawleyNecrosisLiver Neoplasms ExperimentalParenchymamedicineAnimalsEthionineBile ductAntibodies MonoclonalGeneral MedicineImmunohistochemistryEpitheliumCholine DeficiencyRatsBile Ducts Intrahepaticmedicine.anatomical_structureBile Duct NeoplasmsLiverHepatocytemedicine.symptomPrecancerous ConditionsCell DivisionPyruvate kinaseCarcinogenesis
researchProduct

CHARACTERIZATION OF A NEW RAT CELL LINE ESTABLISHED FROM 2′AAF-INDUCED COMBINED HEPATOCELLULAR CHOLANGIOCELLULAR CARCINOMA

2001

A rat cell line-nominated CC-62 derived from a combined hepatocellular and cholangiocellular carcinoma obtained by administration of 2-acetylaminofluorene to male Wistar rats, has been established. Using light and electron microscopy it was determined that morphologically the tumor consisted of a mixed population of hepatocytes and cholangiolar neoplastic cells, intermingled with small, undifferentiated oval-like cells. The CC-62 line has been maintained through 90 passages in culture adopting a paving stone arrangement. Doubling time at the 12th passage was 23 h. Immunostaining with a panel of antisera was performed to identify the cytological profiles of the cell line. There was no k-ras …

MaleCarcinoma HepatocellularC-MetTransplantation HeterologousPopulationCellMice NudeHistogenesisBiologyCholangiocarcinomaMicechemistry.chemical_compoundTumor Cells CulturedCarcinomamedicineAnimalsRats Wistareducationeducation.field_of_studyHepatocyte Growth FactorReverse Transcriptase Polymerase Chain ReactionLiver NeoplasmsDNA NeoplasmCell BiologyGeneral Medicine2-AcetylaminofluoreneProto-Oncogene Proteins c-metAneuploidymedicine.diseaseImmunohistochemistryMolecular biologyRatsTransplantationMicroscopy ElectronBile Ducts IntrahepaticGenes rasmedicine.anatomical_structureBile Duct NeoplasmschemistryCell cultureKaryotypingTumor Suppressor Protein p53ImmunostainingDevelopmental BiologyIn Vitro Cellular & Developmental Biology - Animal
researchProduct

The role of sarcopenia in patients with intrahepatic cholangiocarcinoma: Prognostic marker or hyped parameter?

2019

BACKGROUND & AIMS Sarcopenia has emerged as a prognostic parameter in numerous cancer entities. Current research favours its role as a determining factor for overall survival (OS) in patients with intrahepatic cholangiocarcinoma (ICC); however, it is unclear whether sarcopenia is a truly independent survival predictor if combined with established prognostic factors. METHODS Between 1997-2018, 417 patients with histopathologically confirmed ICC were referred to our centre, of whom 293 were included in this study. Cross-sectional imaging, laboratory examinations and histopathological reports were retrospectively analysed. Psoas muscle index (PMI) as easy-to-measure marker of sarcopenia was ca…

MaleSarcopeniamedicine.medical_specialtyGastroenterologyResectionCholangiocarcinoma03 medical and health sciences0302 clinical medicineRisk FactorsGermanyInternal medicinemedicineHumansIn patientIntrahepatic CholangiocarcinomaAgedPsoas MusclesRetrospective StudiesUnivariate analysisHepatologybusiness.industryCancerMiddle AgedPrognosismedicine.diseaseMagnetic Resonance ImagingSurvival AnalysisPredictive valueBile Duct Neoplasms030220 oncology & carcinogenesisSarcopeniaMultivariate AnalysisCohortFemale030211 gastroenterology & hepatologyTomography X-Ray ComputedbusinessLiver International
researchProduct